By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Statin > Pravastatin

Pravastatin

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|676 words

Pravastatin: A Cholesterol-Lowering Statin Medication

What is Pravastatin?

Pravastatin is a cholesterol-lowering medication that belongs to a class of drugs called statins or HMG-CoA reductase inhibitors. It is primarily prescribed to reduce elevated cholesterol levels and lower the risk of cardiovascular disease in people with high cholesterol or other heart disease risk factors. Pravastatin is available as oral tablets and is typically taken once daily in the evening.

Uses

Pravastatin is approved for several cardiovascular-related conditions:

  • High cholesterol (hypercholesterolemia): Reduces total cholesterol, LDL (“bad”) cholesterol, and triglycerides while modestly increasing HDL (“good”) cholesterol
  • Primary prevention of heart disease: Helps prevent first-time heart attacks and strokes in people with elevated cholesterol and other risk factors
  • Secondary prevention after cardiovascular events: Reduces risk of repeat heart attacks, strokes, and other cardiovascular complications in people with established heart disease
  • Mixed dyslipidemia: Treats conditions involving abnormal levels of multiple blood fats, including elevated triglycerides
  • Familial hypercholesterolemia: Manages inherited forms of high cholesterol that don’t respond adequately to diet and lifestyle changes alone

How it works

Pravastatin works by blocking HMG-CoA reductase, a key enzyme that the liver uses to produce cholesterol. By inhibiting this enzyme, pravastatin reduces the amount of cholesterol manufactured by the liver, which forces the liver to remove more cholesterol from the bloodstream to meet its needs. This mechanism effectively lowers blood cholesterol levels and reduces the formation of arterial plaques that can lead to heart attacks and strokes.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Muscle aches and pains
  • Headache
  • Nausea and stomach upset
  • Diarrhea or constipation
  • Dizziness
  • Fatigue
  • Cold-like symptoms
  • Rash or skin reactions

Serious side effects that require immediate medical attention:

  • Severe muscle pain, weakness, or tenderness (potential sign of rhabdomyolysis)
  • Dark-colored urine or decreased urination
  • Yellowing of skin or eyes (jaundice)
  • Persistent nausea, vomiting, or abdominal pain
  • Unexplained fatigue or weakness

Warnings and precautions

  • Liver disease: People with active liver disease or unexplained elevated liver enzymes should not take pravastatin. Regular liver function monitoring may be recommended during treatment.
  • Pregnancy and breastfeeding: Pravastatin is not recommended during pregnancy or while breastfeeding, as cholesterol is important for fetal development and the drug may pass into breast milk.
  • Muscle problems: Patients with a history of muscle disorders or those taking certain other medications may have increased risk of serious muscle-related side effects.
  • Kidney impairment: Dosage adjustments may be necessary in people with severe kidney disease, and extra monitoring may be required.
  • Age considerations: Elderly patients may be more sensitive to pravastatin’s effects and may require lower starting doses or more frequent monitoring.

Interactions

Pravastatin can interact with several medications and substances:

  • Cyclosporine: Significantly increases pravastatin levels, requiring dose reduction and careful monitoring
  • Gemfibrozil and other fibrates: May increase risk of muscle problems when combined with pravastatin
  • Niacin (high doses): Can increase the risk of muscle-related side effects when used with statins
  • Warfarin and other blood thinners: May enhance anticoagulant effects, requiring more frequent INR monitoring
  • Colestipol and cholestyramine: These bile acid sequestrants can reduce pravastatin absorption if taken simultaneously
  • Clarithromycin and erythromycin: These antibiotics may increase pravastatin concentrations
  • Grapefruit juice: Unlike some other statins, pravastatin has minimal interaction with grapefruit juice
  • Alcohol: Excessive alcohol consumption may increase risk of liver problems when combined with pravastatin

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult starting dose of pravastatin ranges from 10 to 40 mg taken once daily, usually in the evening. The dose may be adjusted based on individual response and cholesterol levels, with a maximum recommended dose of 80 mg daily. For elderly patients or those with kidney impairment, lower starting doses of 10-20 mg may be appropriate. Children and adolescents with familial hypercholesterolemia may be prescribed lower doses based on age and weight. Dosage should always be determined and monitored by a qualified healthcare provider, who will consider individual risk factors, other medications, and treatment goals when prescribing pravastatin.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Pravastatin." GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/drug/pravastatin-2/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Tracing transgender identity through history: Evidence from ancient civilizations to modern terminology

Historical records from ancient Egypt, Mesopotamia, Greece, and Rome document individuals who…

How Political Pressure on Science Agencies Threatens Public Health Decision-Making

Political interference in federal scientific agencies delays evidence-based decision-making and undermines public…

UK Health and Safety Authorities Issue Joint Warning on Asbestos in Consumer Products

UK regulatory authorities issue joint warning on asbestos contamination in imported consumer…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Atorvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Fluvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Lovastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Rosuvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up